Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor VIIa replacement therapy in factor VII deficiency.

K Brummel Ziedins1, G E Rivard, R L Pouliot

  • 1Department of Biochemistry, University of Vermont, Burlington, Vermont 05405, USA.

Journal of Thrombosis and Haemostasis : JTH
|October 1, 2004
PubMed
Summary

Factor VII deficiency treatment can be improved. Lower doses of recombinant Factor VIIa (recombinant FVIIa) achieve hemostasis in Factor VII-deficient individuals, suggesting revised therapeutic strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thrombopoietin levels in Quebec platelet disorder-Implications for the mechanism of thrombocytopenia.

International journal of laboratory hematology·2018
Same author

Vaccinations are not associated with inhibitor development in boys with severe haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Severe bleeding diatheses in an elderly patient with combined type autoantibody against factor XIII A subunit; novel approach to the diagnosis and classification of anti-factor XIII antibodies.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Molecular phenotype and bleeding risks of an inherited platelet disorder in a family with a RUNX1 frameshift mutation.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Factor IX inhibitors and anaphylaxis in haemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Area of Science:

  • Hematology
  • Biochemistry
  • Pharmacology

Background:

  • Factor VII (FVII) deficiency is a rare autosomal recessive bleeding disorder.
  • Current replacement therapies for FVII deficiency are not universally available.
  • Recombinant FVIIa is used as a therapeutic substitute, but optimal dosing is debated.

Purpose of the Study:

  • To determine the FVIIa levels required for hemostasis in FVII-deficient individuals.
  • To compare the efficacy of lower recombinant FVIIa doses with current treatment protocols.
  • To inform potential adjustments in FVII deficiency therapeutic strategies.

Main Methods:

  • Utilized computational, synthetic, and in vitro whole blood coagulation models.
  • Assessed coagulation profiles, including clot time and thrombin generation.

Related Experiment Videos

  • Administered prophylactic doses of recombinant FVIIa to cross-reacting material-negative (CRM-) FVII-deficient subjects.

    • Main Results:

    • Established a 'normalized' coagulation profile for FVII-deficient individuals in a non-bleeding state.
    • Demonstrated that a prophylactic dose of 23 μg kg⁻¹ recombinant FVIIa normalized coagulation profiles 6-8 hours post-infusion in CRM- subjects.
    • Identified an effective FVIIa concentration of 0.3-0.7 nmol L⁻¹ (0.8-1.8 μg kg⁻¹), approximately 1/10th of current therapeutic doses.

    Conclusions:

    • Lower prophylactic doses of recombinant FVIIa can achieve effective hemostasis in FVII deficiency.
    • Therapeutic strategies for FVII deficiency should be reconsidered based on FVII zymogen concentration.
    • This finding has significant implications for optimizing FVII deficiency treatment and resource utilization.